Latest Breaking News On - Lajos pusztai - Page 1 : comparemela.com

Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care

Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited statesErin cobainAgendia mammaprintAlejandro rios hoyoTerri clevengerJoyce oshaughnessyAmerican society of clinical oncology annual meetingMd baylor sammons cancer centerAssociation of mammaprintMd university of michigan rogel cancer centerAmerican societyClinical oncology annual meetingMammaprint indexJoyceo shaughnessySammons cancer center

New research and treatment advances from Yale Canc

New research and treatment advances from Yale Canc
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

United statesPamela kunzMichael cecchiniPat lorussoDaniel petrylakBarbara burtnessRoy herbstFerrigno guajardoYale cancer centerYale school of medicineAmerican society of clinical oncologyYale schoolAmerican societyClinical oncologyCancer careFrom comfort

New Research and Treatment Advances From Yale Canc

New Research and Treatment Advances From Yale Canc
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel petrylakPat lorussoMichael cecchiniPamela kunzFerrigno guajardoRoy herbstBarbara burtnessYale school of medicineYale cancer centerAmerican society of clinical oncologyYale schoolAmerican societyClinical oncologyCancer careFrom comfort

PD-L1 Subgroup Benefits Most From Neoadjuvant Immunotherapy in Early Breast Cancer

Lajos Pusztai reviews the two 'potentially paradigm-shifting trials'

San antonioUnited statesNew havenGreg laubYale school of medicineSan antonio breast cancer symposiumMedpage todayLajos pusztaiYale schoolSan antonio breast cancerSenior director

Dr Pusztai on the Launch of the DARE Study in ER+/HER2– High-Risk Breast Cancer

Lajos Pusztai, MD, DPhil, discusses the phase 2 DARE trial evaluating circulating tumor DNA-guided second-line adjuvant therapy for patients with high-risk, stage II-III, estrogen receptor-positive, HER2-negative breast cancer, highlighting the importance of researching ctDNA utility in this patient population.

San antonioUnited statesYale cancer centerLajos pusztaiMedical oncologyAntonio breast cancer symposiumOnclive tv